Company intelligence / Profile preview

St Andrews Pharmaceutical Technology

Henley-on-Thames, Oxfordshire, United Kingdomuk.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed Pulzar, a patented radio wave-based device that significantly increases cellular protein and monoclonal antibody yields. Early results in collaboration with Dundee University cancer specialists show promise for improving the cost-effectiveness and scalability of immunotherapy manufacturing. The company recently secured multimillion-pound investment to advance further testing and global deployment of its technology.

Therapeutic areas: ImmunologyOncology
Modalities: Monoclonal antibodyBiologicDevice
Industry: Non-Drug Biotech

Partnerships

University of Dundee cancer specialists

Beyond the preview

Go deeper on St Andrews Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on St Andrews Pharmaceutical Technology.

Explore the full profile